Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases.
暂无分享,去创建一个
P. Brown | M. Mehta | J. Buatti | H. Shih | P. Sneed | K. Beal | A. Sahgal | Brian J. Deegan | S. Braunstein | J. Kirkpatrick | James B. Yu | E. Lou | Jing Li | D. Roberge | C. Tseng | W. Sperduto | P. Sperduto | A. Attia | R. Shanley | K. Jethwa | V. Chiang | A. Olson | J. Molitoris | N. Lockney | L. Masucci | N. Rana | D. Shi | A. Zahra | Nitesh Rana
[1] Wen Jiang,et al. Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). , 2017, International journal of radiation oncology, biology, physics.
[2] K. Walter,et al. Radiotherapy for Brain Metastases From Renal Cell Carcinoma in the Targeted Therapy Era: The University of Rochester Experience , 2017, American journal of clinical oncology.
[3] Jennifer S. Yu,et al. Use of Concurrent TKIs With SRS is Associated With an Increased Rate of Radiation Necrosis Among Patients With Renal Cell Carcinoma Brain Metastasis , 2017 .
[4] P. Brown,et al. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. , 2017, International journal of radiation oncology, biology, physics.
[5] P. Brown,et al. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA) , 2017, JAMA oncology.
[6] Shenhong Wu,et al. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy , 2017, Journal of Hematology & Oncology.
[7] R. Motzer,et al. Systemic Therapy for Metastatic Renal-Cell Carcinoma. , 2017, The New England journal of medicine.
[8] P. Brown,et al. The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. , 2016, International journal of radiation oncology, biology, physics.
[9] Volker W Stieber,et al. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. , 2016, JAMA.
[10] Marchetti Paolo,et al. Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy. , 2016, Therapeutic advances in medical oncology.
[11] G. Cartenì,et al. Recent developments in second and third line therapy of metastatic renal cell carcinoma , 2016, Expert review of anticancer therapy.
[12] K. Ballman,et al. Biomarker: Predictive or Prognostic? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C. Porta,et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma , 2015, British Journal of Cancer.
[14] N. Gebauer,et al. Impact of stereotactic radiosurgery dose on control of cerebral metastases from renal cell carcinoma. , 2015, Anticancer research.
[15] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[16] R. Labianca,et al. Safety and Efficacy of Sunitinib in Patients from Italy with Metastatic Renal Cell Carcinoma: Final Results from an Expanded-Access Trial , 2015, Oncology.
[17] C. Yee,et al. The Effect of Radiation on the Immune Response to Cancers , 2014, International journal of molecular sciences.
[18] T. Choueiri,et al. Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. , 2013, Clinical genitourinary cancer.
[19] Meihua Wang,et al. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. , 2013, International journal of radiation oncology, biology, physics.
[20] N. Haseke,et al. Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer. , 2012, Urologic oncology.
[21] E. Shaw,et al. The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery. , 2012, Journal of neurosurgery.
[22] M. Menon,et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] Xianghua Luo,et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] E. Jonasch,et al. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma , 2011, Cancer.
[25] N. Haseke,et al. Simultaneous anti‐angiogenic therapy and single‐fraction radiosurgery in clinically relevant metastases from renal cell carcinoma , 2011, BJU international.
[26] C. Porta,et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases , 2011, Cancer.
[27] L. Collette,et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] C. Szczylik,et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] Wanling Xie,et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] K. Hess,et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. , 2009, The Lancet. Oncology.
[31] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[32] Hiroki Shirato,et al. Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .
[33] T. Mekhail,et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] A. Twijnstra,et al. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma , 2002, Cancer.
[35] R. Motzer,et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.